To address this issue, an international panel of pathologists (C.L., T.K., T.A.L., K.A.M., P.S., M.T., J.R., M.F.)with expertise in pancreatic pathology and/or in CLDN18.2 testing/reporting met virtually in 3 half-day sessions between September and December 2024 to discuss the requirements for adequate CLDN18 immunohistochemical interpretation and reporting in pancreatic cancer. Here, CLDN18 is linked to familial pancreatic carcinoma.